This Morning's Technical Outlook on Generic Drugs Stocks -- Ironwood Pharma, Pacira Pharma, pSivida, and Tetraphase Pharma
NEW YORK, March 21, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on IRWD, PCRX, PSDV, and TTPH which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), pSivida Corp. (NASDAQ: PSDV), and Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH). Companies in the Generic Drugs space produce pharmaceutical products that are no longer protected by patent. These generic medicines are referred to and prescribed by their generic name rather than by the tradename used by the original company that researched and developed the product. All you have to do is sign up today for this free limited time offer by clicking the link below. www.wallstequities.com/registration
Ironwood Pharmaceutical
Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc.'s shares declined slightly by 0.80%, closing Tuesday's trading session at $14.96. The stock recorded a trading volume of 815,105 shares. Shares of the Company are trading 1.11% above their 50-day moving average. Additionally, shares of Ironwood Pharma, which engages in the research, development, and commercialization of human therapeutic products, have a Relative Strength Index (RSI) of 49.59. Get the full research report on IRWD for free by clicking below at: www.wallstequities.com/registration/?symbol=IRWD
Pacira Pharmaceuticals
On Tuesday, shares in Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc. recorded a trading volume of 958,172 shares. The stock dropped 2.28%, ending the day at $29.98. The Company's shares are trading below their 50-day moving average by 16.36%. Furthermore, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 36.30.
On February 28th, 2018, Pacira Pharma reported its results for Q4 and full year 2017. For Q4 2017, total revenues were $79.1 million, total operating expenses were $70.6 million, and GAAP net income was $4.6 million. For the full year, total revenues were $286.6 million, total operating expenses were $311.6 million, and GAAP net loss was $(42.6) million. PCRX's complimentary research coverage is a few simple steps away at: www.wallstequities.com/registration/?symbol=PCRX
pSivida
Watertown, Massachusetts-based pSivida Corp.'s stock finished the day flat at $1.16 with a total trading volume of 323,329 shares. Shares of the Company have advanced 5.45% in the last month and 2.65% in the previous three months. The stock is trading above its 50-day moving average by 3.11%. Additionally, shares of pSivida, which develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the US and the UK, have an RSI of 51.58.
On March 19th, 2018, pSivida announced that its New Drug Application (NDA) for Durasert three-year treatment for posterior segment uveitis has been accepted by the US FDA for filing. The acceptance of the NDA reflects the FDA's determination that the application is sufficiently complete to permit a substantive review. The application will be subject to a standard review and will have a Prescription Drug User Fee Act date of November 05th, 2018. Register for your free research report on PSDV at: www.wallstequities.com/registration/?symbol=PSDV
Tetraphase Pharmaceuticals
Shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. ended yesterday's session 4.46% lower at $3.00. The stock recorded a trading volume of 1.13 million shares. The Company's shares have advanced 41.51% in the last month. The stock is trading 32.91% below its 50-day moving average. Moreover, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 41.65.
On February 22nd, 2018, research firm WBB Securities initiated a 'Speculative Buy' rating on the Company's stock, with a target price of $6 per share.
On March 01st, 2018, Tetraphase Pharma announced the promotion of Larry Edwards, Chief Commercial Officer, to COO. In his new role, Mr. Edwards will also continue to oversee all aspects of pre-commercialization activities for eravacycline in complicated intra-abdominal infections. Wall St. Equities' downloadable research report on TTPH available at: www.wallstequities.com/registration/?symbol=TTPH
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Morris Capital Inc
Share this article